中国已批准阿斯利康和赛诺菲的长效抗体 Beyfortus，用于帮助预防婴儿和新生儿呼吸道合胞病毒 (RSV) 感染。 China has approved Beyfortus, a long-acting antibody from AstraZeneca and Sanofi, to help prevent respiratory syncytial virus (RSV) infections in babies and newborns.

阿斯利康和赛诺菲的 RSV 婴儿疫苗 Beyfortus 已在中国获得批准。 AstraZeneca and Sanofi's RSV infant vaccine, Beyfortus, has received approval in China. 它已经在美国和欧盟获得批准。 It has already been greenlit in the United States and European Union. 该疫苗旨在用于在新生儿和婴儿的第一个 RSV 季节预防 RSV，已根据三项后期临床研究和广泛的本地临床开发计划获得中国国家药品监督管理局的批准。 The vaccine, intended for the prevention of RSV in neonates and infants for their first RSV season, has been approved by China's National Medical Products Administration based on three late-stage clinical studies and an extensive local clinical development program.